Teva Pharmaceutical Industries TEVA
NYSE TEVA
$37.28 -0.19 (-0.49%)
At close: Aug 20, 2026 · 11:54 AM UTC

Teva Pharmaceutical Industries (TEVA) Change in Receivables (2025 - 2026)

Teva Pharmaceutical Industries' (TEVA) quarterly Change in Receivables came in at $91.0 million in Q2 2026, down 18.02% YoY from $111.0 million in Q2 2025, and up 216.67% on a QoQ basis from -$78.0 million in Q1 2026.

Teva Pharmaceutical Industries (TEVA) Change in Receivables (2025 - 2026) Analysis & Trends

Teva Pharmaceutical Industries (TEVA) has 2 years of Change in Receivables data on file, last reported at $91.0 million in Q2 2026.

  • Quarterly Change in Receivables fell 18.02% year-over-year to $91.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$140.0 million (changed N/A YoY) and the FY2025 annual result came in at -$173.0 million, down 170.61% from the prior year.
  • Change in Receivables grew to $91.0 million in Q2 2026, from -$78.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $111.0 million in Q2 2025 to a low of -$264.0 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Haleon 44.07 Bn 43.10 Bn - -
2 Teva Pharmaceutical Industries 43.41 Bn 39.75 Bn 2.15 Bn 91.00 Mn
3 Zoetis 31.83 Bn 30.15 Bn 1.05 Bn 66.00 Mn
4 Takeda Pharmaceutical 28.77 Bn 22.97 Bn 5.10 Bn -445.26 Mn
5 United Therapeutics 22.27 Bn 19.61 Bn 683.80 Mn -1.70 Mn
6 Viatris 18.76 Bn 17.87 Bn 1.46 Bn 126.50 Mn
7 Neurocrine Biosciences 15.65 Bn 15.26 Bn 935.80 Mn 84.30 Mn
8 Elanco Animal Health 11.93 Bn 11.40 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.16 Bn 10.00 Bn - -
10 Alkermes 8.20 Bn 7.55 Bn 397.90 Mn 48.85 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 91.00 Mn
Jun 30, 2026 91.00 Mn
Mar 31, 2026 -78.00 Mn
Mar 31, 2026 -78.00 Mn
Jun 30, 2025 111.00 Mn
Jun 30, 2025 111.00 Mn
Mar 31, 2025 -264.00 Mn
Mar 31, 2025 -264.00 Mn